Actively Recruiting
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
Led by Shandong Suncadia Medicine Co., Ltd. · Updated on 2026-04-30
60
Participants Needed
2
Research Sites
27 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.
CONDITIONS
Official Title
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, aged 18 years at signing the informed consent form
- Diagnosed with primary aldosteronism
- No use of antihypertensive drugs before screening or stable use of antihypertensive drugs
- Voluntarily signed informed consent and willing to comply with study procedures
- Willing to use highly effective contraception from consent signing until 4 weeks after last dose if of childbearing potential
You will not qualify if you...
- Known secondary causes of hypertension
- Previous or planned adrenal-related surgeries during study period
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m6
- Malignancy within 5 years before screening
- Use of other investigational drugs within 90 days or 5 half-lives before screening
- History of blood donation or loss 400 mL within 3 months or blood transfusion within 2 months
- Known or suspected alcohol or narcotic abuse
- Women pregnant, breastfeeding, planning pregnancy, or unable to adopt effective contraception; men unable to adopt effective contraception
- Abnormal daily routine
- Use of strong CYP3A4 inhibitors/inducers within 1 week before randomization
- Severe infection, trauma, or major surgery within 1 month before screening
- Recent cardiovascular events or planned revascularization
- Clinically significant diseases interfering with trial or safety
- Severe mental disorders or inability to understand/participate in trial
- ALT or AST 3 times upper limit of normal
- Any condition affecting safety or trial evaluation in investigator's judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
2
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Actively Recruiting
Research Team
S
Shenhuan Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here